

# Journal of Visualized Experiments

## Transplantation of Chemogenetically Engineered Cortical Interneuron Progenitors into Early Postnatal Mouse Brains --Manuscript Draft--

<b>Article Type:</b>	Invited Methods Article - JoVE Produced Video
<b>Manuscript Number:</b>	JoVE59568R1
<b>Full Title:</b>	Transplantation of Chemogenetically Engineered Cortical Interneuron Progenitors into Early Postnatal Mouse Brains
<b>Keywords:</b>	cortical interneurons; Embryonic Brain Slices; Focal Brain Slice Electroporation; Cortical Interneuron Precursors Transplantation; DREADDs; CNO injections
<b>Corresponding Author:</b>	Myrto Denaxa Biomedical Sciences Research Center Alexander Fleming Athens, GREECE
<b>Corresponding Author's Institution:</b>	Biomedical Sciences Research Center Alexander Fleming
<b>Corresponding Author E-Mail:</b>	denaxa@fleming.gr
<b>Order of Authors:</b>	Myrto Denaxa Guilherme Neves Juan Burrone Vassilis Pachnis
<b>Additional Information:</b>	
<b>Question</b>	<b>Response</b>
Please indicate whether this article will be Standard Access or Open Access.	Open Access (US\$4,200)
Please indicate the <b>city, state/province, and country</b> where this article will be <b>filmed</b> . Please do not use abbreviations.	London, UK

**TITLE:****Transplantation of Chemogenetically Engineered Cortical Interneuron Progenitors into Early Postnatal Mouse Brains****AUTHORS AND AFFILIATIONS:**

Myrto Denaxa<sup>1,2</sup>, Guilherme Neves<sup>3</sup>, Juan Burrone<sup>3</sup>, Vassilis Pachnis<sup>1</sup>

<sup>1</sup>Nervous System Development and Homeostasis Laboratory, The Francis Crick Institute, London, United Kingdom

<sup>2</sup>Neuroscience Centre, Biomedical Sciences Research Centre "Alexander Fleming", Vari, Greece

<sup>3</sup>Centre for Developmental Neurobiology, King's College London, London, United Kingdom

Corresponding author:

Myrto Denaxa (denaxa@fleming.gr)

Email addresses of co-authors:

Guilherme Neves (guilherme.neves@kcl.ac.uk)

Juan Burrone (juan.burrone@kcl.ac.uk)

Vassilis Pachnis (Vassilis.Pachnis@crick.ac.uk)

**KEYWORDS:**

cortical interneurons, ganglionic eminence, brain slice electroporation, intracranial injections, designer receptors exclusively activated by designer drugs (DREADD)

**SUMMARY:**

Here we present a protocol, designed to use chemogenetic tools to manipulate the activity of cortical interneuron progenitors transplanted into the cortex of early postnatal mice.

**ABSTRACT:**

Neuronal development is regulated by a complex combination of environmental and genetic factors. Assessing the relative contribution of each component is a complicated task, which is particularly difficult in regards to the development of  $\gamma$ -aminobutyric acid (GABA)ergic cortical interneurons (CIs). CIs are the main inhibitory neurons in the cerebral cortex, and they play key roles in neuronal networks, by regulating both the activity of individual pyramidal neurons, as well as the oscillatory behavior of neuronal ensembles. They are generated in transient embryonic structures (medial and caudal ganglionic eminences — MGE and CGE) that are very difficult to efficiently target using in utero electroporation approaches. Interneuron progenitors migrate long distances during normal embryonic development, before they integrate in the cortical circuit. This remarkable ability to disperse and integrate into a developing network can be hijacked by transplanting embryonic interneuron precursors into early post-natal host cortices. Here, we present a protocol that allows genetic modification of embryonic interneuron progenitors using focal ex vivo electroporation. These engineered interneuron precursors are then transplanted into early post-natal host cortices, where they will mature into easily identifiable CIs. This protocol allows the use of multiple genetically encoded tools, or

the ability to regulate the expression of specific genes in interneuron progenitors, in order to investigate the impact of either genetic or environmental variables on the maturation and integration of CIs.

## **INTRODUCTION:**

The function of neuronal networks relies in the existence of a balanced complement of excitatory projection neurons and inhibitory interneurons. Although cortical interneurons (CIs) only represent 20% of all neurons in the mammalian cortices, deficits in their number or function are thought to play a key part in the pathogenesis of neurodevelopmental disorders<sup>1,2</sup>. The study of CI development is challenging because CIs are generated in transient embryonic structures that are hard to access, and they follow a long tangential migration before they reach the pallium and develop their mature anatomical and physiological properties<sup>3</sup>. Both genetic and environmental mechanisms are known that regulate CI development<sup>4</sup>, but it has proven difficult to study the relative contribution of multiple factors.

Many insights in CI development were obtained using in vitro culture systems after isolation of progenitors from the ganglionic eminences<sup>5,6</sup>. One of the great advantages of these methods is the potential to label and genetically modify the isolated progenitors and follow their differentiation in detail, to detect cell-autonomous changes. However, these methods are unable to offer information regarding the interactions between developing interneurons and an active network. We have adapted these protocols, by transplantation of the modified precursors into early post-natal cortex. Interneuron progenitors isolated from embryonic ganglionic eminences are able to survive, disperse and integrate into the host network upon transplantation into the cortex<sup>7,8</sup>. This method has been used to reduce the severity of epileptic seizures in genetic mouse models, and has been proposed as a possible new therapy for different neurodevelopmental disorders<sup>9,10</sup>. A previous protocol describes a procedure to transduce these precursors with viral vectors prior to transplantations<sup>11</sup>. The protocol we describe here also allows the genetic modification of interneurons, but does not require the creation of a viral vector, requiring only plasmid DNA, which greatly increases its flexibility. Some studies reported success in using in utero electroporation to genetically modify interneuron progenitors in the caudal ganglionic eminences (CGE)<sup>12</sup>, but this method has proven very difficult to reproduce.

In the representative results section, we illustrate the use of this method to express designer receptors exclusively activated by designer drugs (DREADDs<sup>13</sup>) in the transplanted CIs, a method we used in a recent publication<sup>14</sup>. We expressed hM3D(Gq), an engineered receptor based on the human cholinergic receptor CHRM3, which does not affect neuronal function unless it binds its specific ligand clozapine-N-oxide (CNO). CNO administration selectively triggers activation of hM3D(Gq) expressing cells. We used this method to show that cell autonomous and transient depolarization is sufficient to prevent apoptosis of CIs during development<sup>14</sup>. Combined with different genetically encoded tools, this protocol has the potential to up- or down-regulate gene expression, and visualize or manipulate cell activity during different stages of interneuron differentiation.

**PROTOCOL:**

Animals were bred and housed in accordance with the United Kingdom Animals (Scientific Procedures) Act (1986).

NOTE: For the generation of the pCAGGs-hM3D(Gq)-IRES-RFP construct, a Sall-Stul fragment, containing the hM3D(Gq) sequence, has been isolated from plasmid 50463 (Addgene), and inserted into the expression vector pCAGGs-RFP (gift from F. Guillemot) digested with XhoI-EcoRV.

**1. Preparation of mouse embryo cortical slices**

1.1. Sterilize lab equipment (e.g., stereo microscopes) and surfaces (e.g., benches) with an appropriate detergent solvent and 70% ethanol (EtOH) solution in water (H<sub>2</sub>O).

1.2. Use dissection tools that have been autoclaved and keep them all the time in 100% EtOH.

1.3. Prepare three 20 mL aliquots of 4% low-gelling temperature agarose in 1x phosphate buffer solution (PBS), in 50 mL tubes, and keep them at 55 °C.

1.4. Sacrifice pregnant mice by cervical dislocation at 13.5 or 14.5 days of gestation (embryonic day E13.5–E14.5).

1.5. With a pair of dissection scissors, open the abdomen of the pregnant mice, remove the uterine horns (with the embryos) and place them in ice-cold Krebs solution (**Table 1**), in a 90 mm Petri dish.

1.6. With a pair of straight student fine forceps, open the amniotic sacs, remove the embryos and transfer them in fresh ice-cold Krebs solution, in a new 90 mm Petri dish. Dissect the mouse embryo brain (forebrain, midbrain, hindbrain) from the rest of the embryo body.

1.7. Holding the dissected brains from the hindbrain, transfer them in ice-cold Krebs solution in a new 90 mm Petri dish, and keep them on ice.

1.8. With a waterproof pen, draw a straight line at the outside surface, in the middle of the bottom part of six 35 mm Petri dishes.

1.9. Place one 4% low-gelling agarose/PBS 20 mL aliquot at 37 °C for 5 min. Immediately afterwards pour 10 mL in two 35 mm Petri dishes and embed the dissected brains.

NOTE: The olfactory bulbs should face downwards (bottom of the Petri dish). Embed 4 brains per Petri dish, align them in the straight line previously drawn. Leave 3–5 mm space between each two brains.

1.10. Repeat steps 1.8 and 1.9 until all dissected brains have been embedded.

1.11. Place the embedded brains at 4 °C, in order for the agarose to solidify, and subsequently carve the four brains into a single block of appropriate size and orientation.

NOTE: Leave approximately 3 mm around the edges of the brain samples. Change the orientation of the brains, with the olfactory bulbs on the top.

1.12. Glue the block on the surface of a microtome base and using a surgical blade cut all the way through the bottom of the block, between each two brains, in order to create 4 independent blocks (each mini block containing one brain).

1.13. Section the blocks, in ice-cold Krebs solution, into 250 µm thick slices, using a vibrating blade microtome.

1.14. With a bended flat-ended micro-spatula collect only the slices containing the medial or caudal ganglionic eminences (MGE or CGE; **Figure 1**) and individually transfer them onto filter membranes (13 µm diameter, 8.0 µm pore size), floating on minimal essential medium (MEM, **Table 1**) in polystyrene center-well organ culture dishes (60 mm x 15 mm).

1.15. Place the dishes in a CO<sub>2</sub> tissue culture incubator, at 37 °C, for 1 h, and prepare for the focal electroporation.

## 2. Acute brain slice electroporation

2.1. Before beginning the electroporation procedure, prepare 50 mL of 1% agarose gel in a 100 mm Petri dish. Leave the agarose gel to solidify at room temperature (RT) for approximately 30 min.

2.2. Prepare tiny agarose columns (1 mm diameter and 10 mm length), punched with a glass pipette (225 mm length; 2 mL capacity) and transfer them in ice-cold Krebs solutions.

NOTE: A rubber dropper bulb suitable for 2 mL pipettes is attached to the pipette, and by pressing it the column can be released from the glass pipette to the Krebs solution.

2.3. With a surgical blade, cut small agarose blocks of two sizes: a small one that will fit on the surface of the electrode (see below) and a bigger one, which will be used as a base for performing the focal DNA injections into the brain slices. Transfer the agarose blocks in ice-cold Krebs solution as well.

2.4. Prepare the set-up for the focal injections and the acute electroporation (**Figure 2**).

NOTE: For the injections, the following equipment is needed: 1) a bright field dissection stereo-microscope, 2) a pneumatic pico-pump injector, 3) a micromanipulator, 4) a magnetic stand, and 5) a steel base plate. For the acute slice electroporation, the following equipment is

needed: 1) one square platinum 10 mm Petri dish electrode, 2) one square platinum 10 mm cover electrode, 3) a micromanipulator, and 4) an electroporator.

## 2.5. Focal DNA injections

2.5.1. Prepare a DNA mixture of expression vectors: pCAGGs-IRES-GFP (control vector) + pCAGGs-hM3D(Gq)-IRES-RFP, at a concentration of 1  $\mu\text{g}/\mu\text{L}$  for each vector and add fast green solution (stock 25 mg/mL) in a 1/10 dilution.

2.5.2. Fill a pulled glass micropipette (0.5 mm inner diameter and 1 mm outer diameter) with 10  $\mu\text{L}$  of the DNA mixture and inject small amounts (on the 25–50 nL range) into the selected region (MGE/CGE) of the slice (**Figure 1** and **Figure 2**).

## 2.6. Acute electroporation

NOTE: The electroporation should be performed immediately after the focal DNA injection.

2.6.1. Place the small agarose block on the Petri dish electrode and attach the agarose column to the mobile cover electrode with the help of a flat-ended micro-spatula.

2.6.2. Transfer the slice with its supporting membrane onto the agarose block and place the top electrode with the agarose column on top of the selected region (MGE/CGE) of the slice.

NOTE: Charging voltages of 125 V (two pulses of 5 ms each, interval 500 ms) will yield a successful electroporation (**Figure 3**).

2.7. After the electroporation, place the slice with its supporting membrane into the dish and transfer the dish in a CO<sub>2</sub> tissue culture incubator, at 37 °C.

2.8. After 1 h, exchange the MEM medium for a basic medium appropriate for primary neuronal cultures (neuron basic medium; **Table 1**) and incubate the slices overnight, for approximately 18–24 h.

## 3. Preparation of cell-grafts

3.1. Check the efficiency of the electroporation in all slices. Select only the slices where an acceptable number of fluorescent cells is observed (**Figure 3**).

NOTE: Electroporate approximately 30 slices/per experiment in order to acquire the appropriate number of cells for grafting (see below).

3.2. Dissect the selected region (MGE/CGE) from each slice and cut the tissue into small pieces in ice cold Krebs solution, under a fluorescent dissection stereo-microscope.

221 3.3. Meanwhile, place a 1.5 mL tube with 900 µL neuron basic medium in a water bath at 37 °C.

222  
223 3.4. Transfer the tissue pieces with a P1000 micropipettor to a 1.5 mL tube containing 500 µL of  
224 L15/DNase medium prepared by adding 100 µL of 1 mg/mL DNase stock in DMEM/F12 medium  
225 into 900 µL of L15 medium. Wash the tissue pieces by tapping.

226  
227 3.5. Add 100 µL of DNase (stock 1 mg/mL in DMEM/F12 medium) into the 900 µL neuron basic  
228 medium.

229  
230 3.6. Discard the L15/DNase medium and resuspend the tissue pieces in 200 µL neuron  
231 basic/DNase medium prepared in step 3.5.

232  
233 3.7. Set a P200 micropipettor to 180 µL and mechanically dissociate the tissue pieces by  
234 pipetting up and down gently, 20–30 times, until a smooth and “creamy” suspension is  
235 obtained.

236  
237 3.8. Add 200 µL of neuron basic/DNase medium (final total volume 400 µL) and resuspend.

238  
239 3.9. Take a 4 µL aliquot of cells, dilute appropriately and mount on a haemocytometer.

240  
241 3.10. Under a bright field microscope, check the efficiency of the dissociation and count the  
242 number of cells.

243  
244 NOTE: If the dissociation is successful, bright (alive) single cells and not cell-aggregates will be  
245 observed.

246  
247 3.11. Centrifuge cell suspension from step 3.8, at 1000 rpm, at RT, for 5 min, and subsequently,  
248 remove the supernatant from the tube and add the appropriate L15/DNase medium (usually  
249 5–7 µL) so that the final concentration of cells will be  $8 \times 10^5$ – $1.2 \times 10^6$  cells/µL.

250  
251 NOTE: During the resuspension, it is extremely important to avoid air bubbles.

252  
253 3.12. Place the cell aliquot on ice and have additional L15/DNase medium for the injections.

#### 254 255 **4. Intracranial injections**

256  
257 NOTE: The following procedures take place in a procedure room within the Animal House  
258 Facility. Since the cells will be injected directly to the brain of newborn pups without exposing  
259 the brain, aseptic conditions are kept by sterilizing the working space with 70% EtOH solution  
260 and using autoclaved glass needles. The following equipment is needed for the intracranial  
261 injections: 1) a bright field dissection stereo-microscope, 2) a micro-injector, and 3) a heating  
262 pad for mouse recovery.

4.1. Prepare a glass needle by pulling needles according to the manufacturer's recommendations. Glass needles with an 80  $\mu\text{m}$  outer diameter, 40  $\mu\text{m}$  inner diameter, and a 30° bevel are used in this protocol.

NOTE: As mentioned above, needles should be autoclaved before use.

4.2. Backfill manually the needle with biologically inert oil using a 30 G 2-inch needle and a syringe.

4.3. Assemble and insert the needle to the injector unit according to the manufacturer's instructions.

4.4. Determine the injection settings at maximum volume (69 nL) and a relative slow rate (23 nL/s).

4.5. Empty the needle until the plunger is fully extended.

4.6. Fill the needle.

4.6.1. Cut a small piece from a grafting tape and place it under a bright field dissection stereo-microscope. With a P10 micropipette, transfer 5  $\mu\text{L}$  from the sample (cell aliquot) onto the tape, so that a spherical drop is formed.

4.6.2. Place the tip of the needle into the sample and fill the needle (the plunger retracts and draws the sample with it).

NOTE: Since the sample should be quite viscous, fill the needle in small steps so that the sample will equilibrate, and at a slow rate that prevents bubbles from forming. The sample should be smooth and homogeneous within the needle. If the sample is too viscous and it is not possible to fill the needle, add as much L15/DNase medium as it is required to obtain the correct viscosity. Nevertheless, this will change the concentration of the sample, and ideally should be avoided.

4.7. Anaesthetize new born pups (postnatal day 0–2 [P0-P2]) on ice for 2–5 min.

NOTE: Make sure that the pup is not moving.

4.8. Place the anaesthetized pup under the bright field dissection stereo-microscope.

4.9. Perform 3–4 injections of 69 nL each in each hemisphere.

NOTE: The injection sites are located approximately 1 mm lateral to the midline, and between 1 mm caudal to bregma and 1 mm rostral to the interaural line. The tip of the needle should be



placed approximately 1 mm deep to the pial surface. After each injection, the needle is left in place for approximately 30 s and withdrawn in periods.

4.10. Immediately after the injections, place the pup on a heating pad with the heating at its lowest setting (37 °C). When the pup recovers transfer it to the cage with its mother.

NOTE: Never leave the mother with no pups in the cage. The whole procedure (from removing the pup from its littermates, until it is returned) should last less than 10 min.

## 5. Clozapine-N-oxide injections

5.1. Prepare the DREADD ligand, CNO stock solution by diluting 1 mg of CNO in 50 µL of dimethyl sulfoxide (DMSO) until the solution is translucent. Top-up to 10 mL with saline so that the final concentration of CNO is 0.1 mg/mL.

NOTE: DMSO is toxic. Avoid using it to a concentration higher than 0.1%. Use as a control a saline solution containing the same DMSO concentration as the CNO containing solution.

5.2. From postnatal day 14 and for 3 constitutively days (P14–P16), in each mouse perform two intraperitoneal (I.P.) injections of CNO (CNO concentration: 1 mg/kg) or 0.05% DMSO in saline, per day, 12 h apart.

5.3. On the last day (P17), perform a single injection and sacrifice mice by cervical dislocation within a time window of 30 min–1 h.

## REPRESENTATIVE RESULTS:

Using the procedure presented here, we tested whether the survival of cortical interneurons during early postnatal stages is regulated by activity in a cell autonomous manner. We performed 3 brain slice electroporation experiments (12–16 embryos [E14.5 embryos] per experiment) with the pCAGGs-IRES-GFP (control) and pCAGGs-hM3D(Gq)-IRES-RFP expression vectors, at a concentration of 1 µg/µL for each construct. In our electroporation experiments, only a fraction (approximately 50%; **Figure 3**) of the GFP<sup>+</sup> neurons co-expressed hM3D(Gq) (RFP<sup>+</sup>) and therefore the GFP<sup>+</sup>RFP<sup>-</sup> population served as an internal control for the effect of DREADD ligands. Transfected cortical embryonic interneurons were mechanically dissociated and the resulting cell suspension (8 x 10<sup>5</sup> cells/µL) grafted in the cortex of P0–P1 wild type mice. We had performed 6 injections per brain. In each experiment, a minimum of 6 new born pups were injected. Administration of CNO selectively increased the activity of transfected RFP<sup>+</sup> cells, as demonstrated by the expression of the activity-dependent protein cFos (**Figure 4**). CNO treatment according to the described protocol (administer twice daily P14–P17) resulted in an increase in the proportion of GFP<sup>+</sup>RFP<sup>+</sup> relative to GFP<sup>+</sup>RFP<sup>-</sup> cells, in comparison to vehicle (0.5% DMSO in saline) administered littermates (**Figure 5**).

## FIGURE AND TABLE LEGENDS:

**Figure 1: Representative telencephalic slices used for acute electroporation experiments.** (A-C) Telencephalic slices obtained at three distinct sequential rostro-caudal levels, stained with 4',6-diamidino-2-phenylindole (DAPI). LGE: lateral ganglionic eminence; MGE: medial ganglionic eminence; CGE: caudal ganglionic eminence. Scale bars: 200  $\mu$ m. The yellow asterisks indicate the electroporation site in each slice. The white line marks the edge of the ganglionic eminence.

**Figure 2: Schematic representation of the experimental workflow.** (A) Mouse brain slices are electroporated with appropriate constructs, and (B) after 12 h modified cortical interneuron (CI) precursors are isolated and (C) transplanted in the pallium of newborn mouse pups (P0–P2). In order to modify the activity of immature CIs, P14 pups that had received cell transplantations were injected with CNO or vehicle for four constitutive days according to the presented protocol. (A') Photograph of the acute mouse brain slice electroporation set-up.

**Figure 3: Representative successful acute slice electroporation experiment.** (A) Representative coronal section from an E14.5 embryo brain transfected in the CGE with both pCAGGs-IRES-GFP (GFP) and pCAGGs-hM3D(Gq)-IRES-RFP (RFP) plasmids and cultured for 12 h. The section has been immunostained for GFP (A, B, C) and RFP (A, B, D). The boxed area in panel A is magnified to show the expression of both fluorescent reporters (B), GFP (C) and RFP only (D). The white line marks the edge of the ganglionic eminence. B-D: same photo, different channels or combination of the two different channels. Scale bars: A = 200  $\mu$ m, B-D = 100  $\mu$ m. This figure has been modified from Denaxa et al.<sup>14</sup>.

**Figure 4: Cell autonomous increase in the activity of M3D(Gq)-expressing transplanted CIs upon CNO administration.** (A-D) Representative confocal images of a coronal section of a P17 mouse transplanted at P1 with CI precursors transfected with both pCAGGs-IRES-GFP (GFP) and pCAGGs-hM3D(Gq)-IRES-RFP (RFP) plasmids and treated with CNO. The section has been immunostained for GFP (A), RFP (B), and cFos (C). (D) The combined image of A, B and C immunofluorescence (combo). Note that only CIs co-expressing both plasmids (white arrows in A-D) are also cFos<sup>+</sup> compared to CIs expressing only the control-GFP plasmid (yellow arrows in A-D). (E) Quantification of cFos<sup>+</sup>RFP<sup>+</sup> cells found in the pallium of P17 mice transplanted at P1 (normalized to the total RFP<sup>+</sup> population) and treated with vehicle or CNO (N = 2). A-D: same photo, different channels, or combination of the three different channels. Scale bars: 50  $\mu$ m.

**Figure 5: Cell autonomous increase in the activity of CIs enhances survival.** (A-D) Representative confocal images of somatosensory cortex coronal slices of P17 mice transplanted at P0–P2 with CI precursors transfected with both pCAGGs-IRES-GFP (GFP) and pCAGGs-hM3D(Gq)-IRES-RFP (RFP) plasmids and treated with vehicle (A-B) or CNO (C-D). (E) Quantification of RFP<sup>+</sup> cells found in the forebrain of P17 mice transplanted at P0–P2 (normalized to the total GFP<sup>+</sup> population). RFP<sup>+</sup>(vehicle) = 47%  $\pm$  3%, CNO = 61%  $\pm$  3%, p = 0.01, Student's paired sample t test, n = 3 vehicle and 3 CNO, a minimum of 150 cells counted per brain. A and B: same photo, different channels. C and D: same photo, different channels. Scale bars: 50  $\mu$ m. This figure has been modified from Denaxa et al.<sup>14</sup>.

**Table 1: Additional information concerning media used in this protocol.**

## DISCUSSION:

Here we describe a widely accessible methodology to genetically modify the activity of CI precursors to study the impact of intrinsic activity on CI maturation, and/or the effect of activity modulated CIs on the assembly/function of the integrated cortical circuits.

In the past, several labs, including ours, had performed in utero electroporation experiments in order to genetically modify projection neurons<sup>6</sup>. However, in utero electroporation into ganglionic eminences that include CI progenitors is very difficult, due to electrical conduction path problems. In order to solve this problem, a small number of labs are performing ultrasound guided injections followed by electroporation, which is a demanding technique that requires expensive equipment. This protocol provides an alternative to these methodologies which is accessible to the majority of the scientific community.

One of the most challenging aspect of this protocol is to maximize the number of cells that survive in the host cortex to mature stages, when phenotypic analysis is usually performed (very dependent on the experiment design, but typically older than P17). There are three key steps that the investigator should pay attention: (1) The efficiency of the electroporation. This can be maximized by ensuring the purity of DNA plasmids. Only high-quality DNA plasmids (an A<sub>260</sub>/A<sub>280</sub> ratio of 1.9–2.0) should be used for this procedure. We obtain such high-quality DNA preparations by employing cesium chloride DNA purification. Another crucial factor is the promoter that drives the expression of the gene of interest. We found that the pCAGGs vector, which consists of the chicken  $\beta$ -actin promoter, is extremely powerful and can dramatically increase the electroporation efficiency. (2) The number of starting donor embryos. It is important to make sure that a large number (12–16) of embryos of the same stage are electroporated. This number can be increased, if more experimenters are performing embryo dissections and sectioning together, as it important that embryonic cortical slices are obtained, electroporated and transferred to the incubator as soon as possible. (3) It is important to make sure that a great number of cells are injected in each pup to ensure a high chance of transplanted cell survival until mature stages. In addition, this will dramatically improve the likelihood of successful transplants since low density cell preparations will result in uneven mixing of the cells with the medium, which will produce significant variability in the transplanted brains<sup>15</sup>.

The protocol described here was tailored for investigating the role of activity in regulating CI survival in a cell-autonomous manner. The P14–P17 time window for performing the CNO injections was specifically chosen according to published data, which show that the peak of transplanted CI progenitors' cell death occurs during this period<sup>16</sup>. Therefore, this time frame or the frequency of CNO injections might not hold true for other cell types or brain regions, and the investigator should adjust these parameters according to the specific experimental purposes. Finally, the methodology described here for the intracranial injections of CIs is only feasible for P0–P5 pups (depending also on the mouse line background). In principle, any injections over P5 will require thinning or removing of the skull<sup>15</sup>.

One of the key advantages of this protocol is the ability to use new genetically encoded tools to visualize or manipulate the activity of CIs during different stages of differentiation as they integrate into a developing network. With the pace of discovery of new genetically encoded voltage and calcium sensors, as well as new chemogenetic and optogenetic tools, this protocol allows researchers to use them within weeks of release into plasmid repositories, such as Addgene.

#### ACKNOWLEDGMENTS:

This work was supported by an ERC Starter Grant (282047), a Wellcome Trust Investigator Award (095589/Z/11/Z), an FP7 EC DESIRE grant, and a Lister Institute Prize to JB. Work in V.P.'s laboratory is supported by the BBSRC (BB/L022974/1), the UK Medical Research Council (MRC), and the Francis Crick Institute (which receives funding from the MRC, Cancer Research UK, and the Wellcome Trust). The research in M.D. lab was made possible through the grant from the Stavros Niarchos Foundation to the B.S.R.C. "Alexander Fleming", as part of the Foundation's initiative to support the Greek research.


#### DISCLOSURES:


The authors have nothing to disclose.

#### REFERENCES:


1. Marin, O. Interneuron dysfunction in psychiatric disorders. *Nature Review Neuroscience*. **13** (2), 107–120, doi:10.1038/nrn3155 (2012).
2. Glausier, J.R., Lewis, D.A. GABA and schizophrenia: Where we stand and where we need to go. *Schizophrenia Research*. **181**, 2–3, doi:10.1016/j.schres.2017.01.050 (2017).
3. Fishell, G., Rudy, B. Mechanisms of inhibition within the telencephalon: "where the wild things are". *Annual Review Neuroscience*. **34**, 535–567, doi:10.1146/annurev-neuro-061010-113717 (2011).
4. Wamsley, B., Fishell, G. Genetic and activity-dependent mechanisms underlying interneuron diversity. *Nature Review Neuroscience*. **18** (5), 299–309, doi:10.1038/nrn.2017.30 (2017).
5. Xu, Q., Cobos, I., De La Cruz, E., Rubenstein, J.L., Anderson, S.A. Origins of cortical interneuron subtypes. *Journal of Neuroscience*. **24** (11), 2612–2622, doi:10.1523/JNEUROSCI.5667-03.2004 (2004).
6. Denaxa, M. et al. Maturation-promoting activity of SATB1 in MGE-derived cortical interneurons. *Cell Reports*. **2** (5), 1351–1362, doi:10.1016/j.celrep.2012.10.003 (2012).
7. Wichterle, H., Garcia-Verdugo, J.M., Herrera, D.G., Alvarez-Buylla, A. Young neurons from medial ganglionic eminence disperse in adult and embryonic brain. *Nature Neuroscience*. **2** (5), 461–466, doi:10.1038/8131 (1999).
8. Alvarez-Dolado, M. et al. Cortical inhibition modified by embryonic neural precursors grafted into the postnatal brain. *Journal of Neuroscience*. **26** (28), 7380–7389, doi:10.1523/JNEUROSCI.1540-06.2006 (2006).
9. Baraban, S.C. et al. Reduction of seizures by transplantation of cortical GABAergic interneuron precursors into Kv1.1 mutant mice. *Proceedings of the National Academy of Sciences of the United States of America*. **106** (36), 15472–15477, doi:10.1073/pnas.0900141106 (2009).

10. Southwell, D.G. et al. Interneurons from embryonic development to cell-based therapy. *Science*. **344** (6180), 1240622, doi:10.1126/science.1240622 (2014).
11. Vogt, D. et al. Viral-mediated Labeling and Transplantation of Medial Ganglionic Eminence (MGE) Cells for In Vivo Studies. *Journal of Visualized Experiments*. (98), doi:10.3791/52740 (2015).
12. De Marco Garcia, N.V., Karayannis, T., Fishell, G. Neuronal activity is required for the development of specific cortical interneuron subtypes. *Nature*. **472** (7343), 351–355, doi:10.1038/nature09865 (2011).
13. Urban, D.J. Roth, B.L. DREADDs (designer receptors exclusively activated by designer drugs): chemogenetic tools with therapeutic utility. *Annual Review of Pharmacology and Toxicology*. **55**, 399–417, doi:10.1146/annurev-pharmtox-010814-124803 (2015).
14. Denaxa, M. et al. Modulation of Apoptosis Controls Inhibitory Interneuron Number in the Cortex. *Cell Reports*. **22** (7), 1710–1721, doi:10.1016/j.celrep.2018.01.064 (2018).
15. Quatrocolo, G. et al. Homochronic Transplantation of Interneuron Precursors into Early Postnatal Mouse Brains. *Journal of Visualized Experiments*. (136), doi:10.3791/57723 (2018).
16. Southwell, D.G. et al. Intrinsically determined cell death of developing cortical interneurons. *Nature*. **491** (7422), 103–113, doi:10.1038/nature11523 (2012).

















**MEDIA**

KREBS	Chemicals	Concentration
10x KREBS (stock)		
500 mL	NaCl	1.26 M
	KCl	25 mM
	NaH <sub>2</sub> PO <sub>4</sub>	12 mM
	MgCl <sub>2</sub>	12 mM
	CaCl <sub>2</sub>	21 mM
	dH <sub>2</sub> O (sterile)	500 mL
1x KREBS		
500 mL	10x KREBS	50 mL
	Glucose	0.99 gr
	NaHCO <sub>3</sub>	1.05 gr
	dH <sub>2</sub> O (sterile)	450 mL

MEM		
50 mL	MEM with glutamine	43.5 mL
	FCS (Fetal Bovine Serum)	5 mL
	25% Glucose in dH <sub>2</sub> O (sterile)	1 mL
	100x Penicillin/Streptomycin (Pen/Strep)	0.5 mL

Neuron Basic Medium		
50 mL	Neuron Basic Medium	47 mL
	B-27 supplement	1 mL
	25% Glucose in dH <sub>2</sub> O (sterile)	1 mL
	100x Pen/Strep	0.5 mL
	100x Glutamine	0.5 mL

Name of Material/ Equipment	Company
<u>Medium/Supplements</u>	
B-27	GIBCO (ThermoFisher Scientific)
DMEM/F12	GIBCO (ThermoFisher Scientific)
DNase	SIGMA
FBS	GIBCO (ThermoFisher Scientific)
100x Glutamine	GIBCO (ThermoFisher Scientific)
L15	GIBCO (ThermoFisher Scientific)
MEM alpha, GlutaMAX	GIBCO (ThermoFisher Scientific)
Neurobasal medium	GIBCO (ThermoFisher Scientific)
100x P/S	GIBCO (ThermoFisher Scientific)
<u>Equipment</u>	
Electroporator	BTX
Injector for acute slice electroporation	Eppendorf
Injector for cell transplantation (I)	Visual Sonics
Injector for cell transplantation (II)	WPI
Magnetic Stand	WPI
Kite Manual Micromanipulator	WPI
Platinum Electrode (I)	Protech International Inc.
Platinum Electrode (II)	Protech International Inc.
Steel Base Plate	WPI
Vibratome	Leica

### Other Material


Glass capillaries for electroporation      VWR

Glass capillaries for cell transplantation Visual Sonics

Nuclepore 8  $\mu\text{m}$  whatman membrane      SLS

Organ tissue culture dishes      BD Biosciences (Falcon)

Catalog Number	Comments/Description
175040-044	
21331-020	
DN15-100MG	
10270-098	
35050-061	
11415-049	
32561-029	
21103-049	Neuron basic medium
15140-122	
ECM 830 generator	
FemtoJet Microinjector	
Vevo Injector System	
NANOLITER2010	
M10L Magnetic Stand	
KITE-M3-R	
CUY-700-1	
CUY-700-2	
5479	
VT1200S	



1B100-4

provided by Visual Sonics

110414

353037



1 Alewife Center #200  
Cambridge, MA 02140  
tel. 617.945.9051  
www.jove.com

## ARTICLE AND VIDEO LICENSE AGREEMENT - UK

Title of Article:	Transplantation of chemogenetically engineered cortical interneuron progenitors into early postnatal mouse brains
Author(s):	Myrto Denaxa, Guilherme Neves, Juan Burrone, Vassilis Pachnis

Item 1: The Author elects to have the Materials be made available (as described at <http://www.jove.com/publish>) via:

☐ Standard Access

☒ Open Access

Item 2: Please select one of the following items:

☒ The Author is **NOT** a United States government employee.

☐ The Author is a United States government employee and the Materials were prepared in the course of his or her duties as a United States government employee.

☐ The Author is a United States government employee but the Materials were NOT prepared in the course of his or her duties as a United States government employee.

### ARTICLE AND VIDEO LICENSE AGREEMENT

1. **Defined Terms.** As used in this Article and Video License Agreement, the following terms shall have the following meanings: "**Agreement**" means this Article and Video License Agreement; "**Article**" means the article specified on the last page of this Agreement, including any associated materials such as texts, figures, tables, artwork, abstracts, or summaries contained therein; "**Author**" means the author who is a signatory to this Agreement; "**Collective Work**" means a work, such as a periodical issue, anthology or encyclopedia, in which the Materials in their entirety in unmodified form, along with a number of other contributions, constituting separate and independent works in themselves, are assembled into a collective whole; "**CRC License**" means the Creative Commons Attribution 3.0 Agreement (also known as CC-BY), the terms and conditions of which can be found at: <http://creativecommons.org/licenses/by/3.0/us/legalcode>; "**Derivative Work**" means a work based upon the Materials or upon the Materials and other pre-existing works, such as a translation, musical arrangement, dramatization, fictionalization, motion picture version, sound recording, art reproduction, abridgment, condensation, or any other form in which the Materials may be recast, transformed, or adapted; "**Institution**" means the institution, listed on the last page of this Agreement, by which the Author was employed at the time of the creation of the Materials; "**JoVE**" means MyJoVE Corporation, a Massachusetts corporation and the publisher of The Journal of Visualized Experiments; "**Materials**" means the Article and / or the Video; "**Parties**" means the Author and JoVE; "**Video**" means any video(s) made by the Author, alone or in conjunction with any other parties, or by JoVE or its affiliates or agents, individually or in collaboration with the Author or any other parties, incorporating all or any portion

of the Article, and in which the Author may or may not appear.

2. **Background.** The Author, who is the author of the Article, in order to ensure the dissemination and protection of the Article, desires to have the JoVE publish the Article and create and transmit videos based on the Article. In furtherance of such goals, the Parties desire to memorialize in this Agreement the respective rights of each Party in and to the Article and the Video.

3. **Grant of Rights in Article.** In consideration of JoVE agreeing to publish the Article, the Author hereby grants to JoVE, subject to **Sections 4 and 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Article in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Article into other languages, create adaptations, summaries or extracts of the Article or other Derivative Works (including, without limitation, the Video) or Collective Works based on all or any portion of the Article and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats. If the "Open Access" box has been checked in **Item 1** above, JoVE and the Author hereby grant to the public all such rights in the Article as provided in, but subject to all limitations and requirements set forth in, the CRC License.



4. **Retention of Rights in Article.** Notwithstanding the exclusive license granted to JoVE in **Section 3** above, the Author shall, with respect to the Article, retain the non-exclusive right to use all or part of the Article for the non-commercial purpose of giving lectures, presentations or teaching classes, and to post a copy of the Article on the Institution's website or the Author's personal website, in each case provided that a link to the Article on the JoVE website is provided and notice of JoVE's copyright in the Article is included. All non-copyright intellectual property rights in and to the Article, such as patent rights, shall remain with the Author.

5. **Grant of Rights in Video - Standard Access.** This **Section 5** applies if the "Standard Access" box has been checked in **Item 1** above or if no box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby acknowledges and agrees that, subject to **Section 7** below, JoVE is and shall be the sole and exclusive owner of all rights of any nature, including, without limitation, all copyrights, in and to the Video. To the extent that, by law, the Author is deemed, now or at any time in the future, to have any rights of any nature in or to the Video, the Author hereby disclaims all such rights and transfers all such rights to JoVE.

6. **Grant of Rights in Video - Open Access.** This **Section 6** applies only if the "Open Access" box has been checked in **Item 1** above. In consideration of JoVE agreeing to produce, display or otherwise assist with the Video, the Author hereby grants to JoVE, subject to **Section 7** below, the exclusive, royalty-free, perpetual (for the full term of copyright in the Article, including any extensions thereto) license (a) to publish, reproduce, distribute, display and store the Video in all forms, formats and media whether now known or hereafter developed (including without limitation in print, digital and electronic form) throughout the world, (b) to translate the Video into other languages, create adaptations, summaries or extracts of the Video or other Derivative Works or Collective Works based on all or any portion of the Video and exercise all of the rights set forth in (a) above in such translations, adaptations, summaries, extracts, Derivative Works or Collective Works and (c) to license others to do any or all of the above. The foregoing rights may be exercised in all media and formats, whether now known or hereafter devised, and include the right to make such modifications as are technically necessary to exercise the rights in other media and formats.

7. **Government Employees.** If the Author is a United States government employee and the Article was prepared in the course of his or her duties as a United States government employee, as indicated in **Item 2** above, and any of the licenses or grants granted by the Author hereunder exceed the scope of the 17 U.S.C. 403, then the rights granted hereunder shall be limited to the maximum rights permitted under such statute. In such case, all provisions contained herein that are not in conflict with such statute shall remain in full force and effect, and all provisions contained herein that do so conflict shall be

deemed to be amended so as to provide to JoVE the maximum rights permissible within such statute.

8. **Protection of the work.** The Author(s) authorize JoVE to take steps in the Author(s) name and on their behalf if JoVE believes some third party could be infringing or might infringe the copyright of either the Author's Article and/or Video.

9. **Likeness, Privacy, Personality.** The Author hereby grants JoVE the right to use the Author's name, voice, likeness, picture, photograph, image, biography and performance in any way, commercial or otherwise, in connection with the Materials and the sale, promotion and distribution thereof. The Author hereby waives any and all rights he or she may have, relating to his or her appearance in the Video or otherwise relating to the Materials, under all applicable privacy, likeness, personality or similar laws.

10. **Author Warranties.** The Author represents and warrants that the Article is original, that it has not been published, that the copyright interest is owned by the Author (or, if more than one author is listed at the beginning of this Agreement, by such authors collectively) and has not been assigned, licensed, or otherwise transferred to any other party. The Author represents and warrants that the author(s) listed at the top of this Agreement are the only authors of the Materials. If more than one author is listed at the top of this Agreement and if any such author has not entered into a separate Article and Video License Agreement with JoVE relating to the Materials, the Author represents and warrants that the Author has been authorized by each of the other such authors to execute this Agreement on his or her behalf and to bind him or her with respect to the terms of this Agreement as if each of them had been a party hereto as an Author. The Author warrants that the use, reproduction, distribution, public or private performance or display, and/or modification of all or any portion of the Materials does not and will not violate, infringe and/or misappropriate the patent, trademark, intellectual property or other rights of any third party. The Author represents and warrants that it has and will continue to comply with all government, institutional and other regulations, including, without limitation all institutional, laboratory, hospital, ethical, human and animal treatment, privacy, and all other rules, regulations, laws, procedures or guidelines, applicable to the Materials, and that all research involving human and animal subjects has been approved by the Author's relevant institutional review board.

11. **JoVE Discretion.** If the Author requests the assistance of JoVE in producing the Video in the Author's facility, the Author shall ensure that the presence of JoVE employees, agents or independent contractors is in accordance with the relevant regulations of the Author's institution. If more than one author is listed at the beginning of this Agreement, JoVE may, in its sole discretion, elect not take any action with respect to the Article until such time as it has received complete, executed Article and Video License Agreements from each such author. JoVE reserves the right, in its absolute and sole

discretion and without giving any reason therefore, to accept or decline any work submitted to JoVE. JoVE and its employees, agents and independent contractors shall have full, unfettered access to the facilities of the Author or of the Author's institution as necessary to make the Video, whether actually published or not. JoVE has sole discretion as to the method of making and publishing the Materials, including, without limitation, to all decisions regarding editing, lighting, filming, timing of publication, if any, length, quality, content and the like.

12. **Indemnification.** The Author agrees to indemnify JoVE and/or its successors and assigns from and against any and all claims, costs, and expenses, including attorney's fees, arising out of any breach of any warranty or other representations contained herein. The Author further agrees to indemnify and hold harmless JoVE from and against any and all claims, costs, and expenses, including attorney's fees, resulting from the breach by the Author of any representation or warranty contained herein or from allegations or instances of violation of intellectual property rights, damage to the Author's or the Author's institution's facilities, fraud, libel, defamation, research, equipment, experiments, property damage, personal injury, violations of institutional, laboratory, hospital, ethical, human and animal treatment, privacy or other rules, regulations, laws, procedures or guidelines, liabilities and other losses or damages related in any way to the submission of work to JoVE, making of videos by JoVE, or publication in JoVE or elsewhere by JoVE. The Author shall be responsible for, and shall hold JoVE harmless from, damages caused by lack of sterilization, lack of cleanliness or by contamination due to the making of a video by JoVE its employees, agents or independent contractors. All sterilization, cleanliness or


decontamination procedures shall be solely the responsibility of the Author and shall be undertaken at the Author's expense. All indemnifications provided herein shall include JoVE's attorney's fees and costs related to said losses or damages. Such indemnification and holding harmless shall include such losses or damages incurred by, or in connection with, acts or omissions of JoVE, its employees, agents or independent contractors.

13. **Fees.** To cover the cost incurred for publication, JoVE must receive payment before production and publication the Materials. Payment is due in 21 days of invoice. Should the Materials not be published due to an editorial or production decision, these funds will be returned to the Author. Withdrawal by the Author of any submitted Materials after final peer review approval will result in a US\$1,200 fee to cover pre-production expenses incurred by JoVE. If payment is not received by the completion of filming, production and publication of the Materials will be suspended until payment is received.

14. **Transfer, Governing Law.** This Agreement may be assigned by JoVE and shall inure to the benefits of any of JoVE's successors and assignees. This Agreement shall be governed and construed by the internal laws of the Commonwealth of Massachusetts without giving effect to any conflict of law provision thereunder. This Agreement may be executed in counterparts, each of which shall be deemed an original, but all of which together shall be deemed to be one and the same agreement. A signed copy of this Agreement delivered by facsimile, e-mail or other means of electronic transmission shall be deemed to have the same legal effect as delivery of an original signed copy of this Agreement.

A signed copy of this document must be sent with all new submissions. Only one Agreement is required per submission.

# CORRESPONDING AUTHOR

Name:	MYRTO DENAXA	
Department:	NEUROSCIENCE	
Institution:	BSRC "AL. FLEMING"	
Title:	STAVROS NIARCHOS FELLOW / PRINCIPLE INVESTIGATOR	
Signature:		Date: 27/02/19

Please submit a **signed** and **dated** copy of this license by one of the following three methods:

1. Upload an electronic version on the JoVE submission site
2. Fax the document to +1.866.381.2236
3. Mail the document to JoVE / Attn: JoVE Editorial / 1 Alewife Center #200 / Cambridge, MA 02140

We would like to thank the reviewers for their comments. Below we answer the minor points raised (reviewers' comments are printed in italics). Changes to the manuscript main text, included the ones indicated by the JoVE editorial team, are now marked in red type for clarity.

Reviewer #2:

*More details needed on sterile technique: use of 70% ethanol, how do they sterilize their tools, which steps were performed in a biosafety cabinet, how the surgical procedure was kept aseptic.*

We provide these details in the following paragraphs/lines of the manuscript:

Paragraph 2, Preparation of mouse embryo cortical slices: 2.1, 2.2, Lines: 98-101

Paragraph 5, Intracranial injections: Note 1, Lines: 213-216

*More detail on the agarose columns. What is the diameter? What is the length? How are they handled given their small size?*

We provide this information:

Paragraph 3: Acute brain slice electroporation: 3.2, 3.7, Lines: 145-148, 171

*More detail required to define which telencephalic slices are deemed suitable for electroporation. What were the criteria used by the authors? A photograph or diagram would be very helpful here.*

To address this comment, we added a new figure, Figure 1.

*Figures in general need more annotations: For instance, in 2C, explicitly state that this is GFP on the figure itself. This needs to be done throughout.*

We added more annotations in all our figures.

*Figure 2, A: the resolution is too low to appreciate the localization of the electroplated cells. Is that CGE? E14.5?*

We have added the appropriate annotation on the figure and provided the required information in the figure legend.

*Figure 3E: Absence of error bars. Also, x axis label is very difficult to understand. Please consider re-labelling with something clearer.*

We have made the suggested changes and provided the missing information by adding more samples in our quantification.

Since the authors highlight the importance of the DNA quality, they should suggest a protocol or a commercial kit to achieve it.

We provided this information in Discussion, Line: 351.

*What does they mean by "the identity of the plasmid itself can also affect the electroporation efficiency". Is it simply the size of the hM3D(Gq) CDS? The length of the plasmid is an important factor for the efficiency.*

It is true that the size of a construct is important for the efficiency of the electroporation, the bigger the size of the construct the less the efficiency. Nevertheless, we believe that this is not what is happening in our case, since the pCAGGs-hM3D(Gq)-IRES-RFP construct is not very long. We really have no explanation about the fact that only 50% of our GFP electroporated population also express hM3D(Gq)-IRES-RFP. We wanted to make this note, but we understand that it might be confusing, therefore we have removed this comment from our discussion.

*- Is it a typo for the Glass capillaries for electroporation WVWR, should it be VWR?*

We have corrected the typo.

#### JoVE comments

We have made all changes suggested by the JoVE editorial team.

Concerning the scale bars of the images, these are indicated for different images only. If the image is the same but shows a different fluorescent channel we don't have a scale bar. Sufficient explanation is provided in each figure legend.

Concerning the copyright permission to reuse any figures from our previous publication:  
"Modulation of Apoptosis Controls Inhibitory Interneuron Number in the Cortex. *Cell Reports* **22** (7), 1710-1721, Denaxa et al., 2018", we provide the following statement from Cell Reports:

#### **Creative Commons Attribution License (CC BY)**

This article is available under the terms of the [Creative Commons Attribution License \(CC BY\)](#). You may copy and distribute the article, create extracts, abstracts and new works from the article, alter and revise the article, text or data mine the article and otherwise reuse the article commercially (including reuse and/or resale of the article) without permission from Elsevier. You must give appropriate credit to the original work, together with a link to the formal publication through the relevant DOI and a link to the Creative Commons user license above.

You must indicate if any changes are made but not in any way that suggests the licensor endorses you or your use of the work.

Permission is not required for this type of reuse.